Literature DB >> 11731950

Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.

Roger J Pomerantz1.   

Abstract

Highly active antiretroviral therapy (HAART) has led to profound decreases in morbidity and mortality rates in human immunodeficiency virus type 1 (HIV-1)-infected persons, at least in the developed world. Many infected persons have plasma levels of HIV-1 RNA that are less than the limits of detection of most clinical assays as a result of combination antiretroviral therapy. Nonetheless, HIV-1 has not been eradicated by HAART. This has been shown to be because of latent HIV-1 replication-competent provirus in resting CD4+ T lymphocytes, cryptic viral replication below the limits of detection of most clinical assays, and, possibly, the presence of viral sanctuary sites. An understanding of these reservoirs for HIV-1 in the setting of virally suppressive HAART will be critical for the development of new approaches to induce HIV-1 remissions and for the exploration of the possibility of viral eradication in the future.

Entities:  

Mesh:

Year:  2001        PMID: 11731950     DOI: 10.1086/338256

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  Identification of T cell-signaling pathways that stimulate latent HIV in primary cells.

Authors:  David G Brooks; Philip A Arlen; Lianying Gao; Christina M R Kitchen; Jerome A Zack
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

2.  Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.

Authors:  Ronald J Messer; Ulf Dittmer; Karin E Peterson; Kim J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

3.  The viral protein Tat can inhibit the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Björn D Kuhl; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

4.  Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia.

Authors:  Jennifer L McDermott; Isabella Martini; Davide Ferrari; Francesca Bertolotti; Claudio Giacomazzi; Giuseppe Murdaca; Francesco Puppo; Francesco Indiveri; Oliviero E Varnier
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Inhibition of human immunodeficiency virus type 1 replication in latently infected cells by a novel IkappaB kinase inhibitor.

Authors:  Ann Florence B Victoriano; Kaori Asamitsu; Yurina Hibi; Kenichi Imai; Nina G Barzaga; Takashi Okamoto
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 6.  Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.

Authors:  Mayte Coiras; María Rosa López-Huertas; Mayte Pérez-Olmeda; José Alcamí
Journal:  Nat Rev Microbiol       Date:  2009-11       Impact factor: 60.633

7.  Rational design of drugs that induce human immunodeficiency virus replication.

Authors:  Dean H Hamer; Sven Bocklandt; Louise McHugh; Tae-Wook Chun; Peter M Blumberg; Dina M Sigano; Victor E Marquez
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Authors:  Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Primary cell model for activation-inducible human immunodeficiency virus.

Authors:  Bryan Burke; Helen J Brown; Matthew D Marsden; Gregory Bristol; Dimitrios N Vatakis; Jerome A Zack
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

Review 10.  Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.

Authors:  Simi Gunaseelan; Krishnan Gunaseelan; Manjeet Deshmukh; Xiaoping Zhang; Patrick J Sinko
Journal:  Adv Drug Deliv Rev       Date:  2009-11-24       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.